more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates

Research Report
  ()
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch.
Tags: Biotechnology / Pharmaceuticals

Silver Break Out Confirmed

Contributed Opinion
  ()
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell.
Tags: SilverBiotechnology / PharmaceuticalsGold

NY Biopharma Shares Promising Clinical Data

Research Report
  ()
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.

Research Report
  ()
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.
Tags: Biotechnology / Pharmaceuticals

Mass. Biotech Receives FDA Approval

Research Report
  ()
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

CT Biotech Ready for Clinical Milestones

Research Report
  ()
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial

Research Report
  ()
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton.
Tags: Biotechnology / Pharmaceuticals

New Jersey Biotech Reports Positive Survival Data

Research Report
  ()
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price.
Tags: Biotechnology / Pharmaceuticals

California Biotech's Target Price 200% Higher Than Current

Research Report
  ()
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients.
Tags: Biotechnology / Pharmaceuticals

Target Price Raised on Biotech Co.

Research Report
  ()
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company.
Tags: Biotechnology / Pharmaceuticals

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment

Research Report
  ()
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note.
Tags: Biotechnology / Pharmaceuticals

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine

  ()
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

Is It Now Time To Buy This Biotech Stock?

Contributed Opinion
  ()
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows.
Tags: Biotechnology / PharmaceuticalsMedical Devices

California Biotech Reports Positive QOL Improvements in Program

Research Report
  ()
With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment

  ()
Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Biotech Working on 'Functional Cure' for Type 1 Diabetes

  ()
Clinical-stage biotechnology company Sernova Corp.'s (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) Cell Pouch implantable technology can act as a "pseudo-organ," delivering therapeutic cells to the body. Find out why one newsletter author thinks the stock could deliver a big payoff for shareholders and for patients.
Tags: Biotechnology / Pharmaceuticals

MA Biotech Reports Positive Meeting with FDA

Research Report
  ()
Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

Mass. Biopharma Reports Positive Data and Announces New Program

Research Report
  ()
Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts.
Tags: Biotechnology / Pharmaceuticals

Pharma Co. Enrolls First Patient in Trial

Research Report
  ()
Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy.
Tags: Biotechnology / Pharmaceuticals

Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial

  ()
Florida-based Cyclo Therapeutics Inc. (CYTH:NASDAQ) says it has completed enrollment in its "pivotal" TransportNPC trial of Niiemann-Pick Type C1, a rare progressive genetic disorder. Find out why analysts are recommending the stock.
Tags: Biotechnology / Pharmaceuticals

Promising Clinical Data and Strategic Partnerships Propel Oncology Co.

  ()
Elevation Oncology Inc.(ELEV:NASDAQ) reported its second-quarter 2024 financial results on August 6, highlighting significant progress in its clinical trials and ongoing business achievements. Read on to see why three experts believe this stock is a Buy.
Tags: Biotechnology / Pharmaceuticals

Boston Biotech Reports Promising Interim Data

Research Report
  ()
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Analyst Says CA Pharma Underappreciated by Investors

Research Report
  ()
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors.
Tags: Biotechnology / Pharmaceuticals

Analyst's Target Price for Biotech Massively Higher Than Current Price

Research Report
  ()
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price.
Tags: Biotechnology / Pharmaceuticals

Study Shows 93% Cough Suppression With Co.'s Drug

  ()
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market."
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 41 Next